Research Renaissance: Exploring the Future of Brain Science

Karen Toffler Charitable Trust
  • 0.0 (0)
  • Life Sciences

Welcome to Research Renaissance, presented by the Karen Toffler Charitable Trust. We invite you into the stories, struggles, and breakthroughs shaping the future of human health. From cutting-edge brain science to discoveries transforming how we heal, adapt, and thrive, we explore the ideas that matter and the people behind them. Each episode features early-career researchers driven by curiosity, entrepreneurs turning bold ideas into lifesaving innovations, and leaders in investment, policy, and research who help move discoveries into the real world. Together, we look across diseases, technologies, and research fields to understand not just what is changing, but why it matters—for patients, families, and the future we all share. Join us as we uncover new insights, spark collaboration, and illuminate the science that can improve lives.

  1. 1d ago

    Rethinking Neurodegeneration: The Hidden Role of Blood Vessels in Alzheimer's Disease

    What if the blood vessels in your brain aren't just collateral damage in Alzheimer's disease, but part of the cause? Dr. Rachel Bennett, associate professor at Massachusetts General Hospital and Harvard Medical School, is challenging one of the field's longest-held assumptions. In this episode, she joins host Deborah Westfall to break down her groundbreaking research on the relationship between tau pathology and vascular dysfunction, and why the future of Alzheimer's science may look nothing like what we expect today. What You'll Learn in This Episode Why vascular changes in Alzheimer's disease were historically treated as secondary damage, and why that thinking is shiftingHow Dr. Bennett's lab discovered that tau pathology alone can drive abnormal changes in blood vessel structureThe thick-tissue imaging technique that revealed something thin slides had been missing for decadesWhat 47 meters of blood vessels in a single brain fold tells us about the scale of this problemWhy the field may be drastically underestimating the number of distinct Alzheimer's disease subtypesHow AI and spatial transcriptomics are accelerating discoveries that would have taken years under traditional funding timelinesThe critical role of philanthropic funding for early-career researchers, and why smaller, faster grants can outperform traditional NIH timelinesAbout Dr. Rachel Bennett Dr. Rachel Bennett is an associate professor at Massachusetts General Hospital and Harvard Medical School, and a 2024 and 2025 Toffler Scholar. She runs the Bennett Alz Lab, which focuses on vascular contributions to Alzheimer's disease using cutting-edge imaging techniques including light sheet microscopy, in vivo two-photon microscopy, and spatial transcriptomics. She completed her PhD at Washington University in St. Louis studying traumatic brain injury and microglia, and her postdoctoral training in the lab of Dr. Bradley Hyman at MGH. Resources and Links Bennett Alz Lab: bennettallzlab.comConnect with Dr. Bennett on LinkedInKaren Toffler Charitable Trust: karrentoffler.orgMassachusetts Alzheimer's Disease Research Center (Massachusetts ADRC)Research referenced: Acta Neuropathologica (tau and vascular accumulation study) If this episode opened your eyes to a new side of Alzheimer's research, please leave a review on Apple Podcasts or Spotify. Share it with someone who cares about brain health, and subscribe so you never miss an episode of Research Renaissance. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    46 min

  2. Jun 17

    How Early Life Adversity Rewires the Developing Brain

    What if the roots of anxiety, depression, and early puberty trace back to the first years of life — and we've been asking the wrong questions? In this episode, host Deborah Westphal sits down with Angarika Balakrishnan, PhD candidate at the Brenhouse Lab at Northeastern University, whose research links early-life adversity to long-term brain development, neuroendocrine disruption, and mental health outcomes. Key Takeaways Early-life adversity is not a single variable — timing, type, and predictability each produce different biological signatures in the developing brainThe CRHR1 receptor in the hypothalamus may be a targetable mechanism for preventing early-onset puberty and adolescent anxietyExercise during adolescence could serve as a treatment paradigm for metabolic, immune, and cognitive outcomes linked to early stressDepression, anxiety, and PTSD share underlying circuitry — treating them as separate conditions has slowed progressScience rewards certainty over doubt, and that culture is driving a mental health crisis inside PhD programs About Angarika PhD candidate, Brenhouse Lab, Northeastern University. Recently published in Hormones and Behavior and Neurobiology of Stress. Research supported by the Karen Toffler Charitable Trust. Enjoyed this episode? Subscribe, leave a review, and share with anyone passionate about brain science or mental health. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    55 min

  3. Jun 10

    The Eye Knows: Using Ocular Biometrics to Diagnose PTSD, Anxiety, and Depression

    What if diagnosing PTSD, anxiety, and depression could be as objective as a blood test — done in 10 minutes on your phone? That's the vision behind Sensei, a company using AI and ocular biometrics to bring measurable, objective diagnostics to mental health. In this episode, host Deborah Westphal sits down with David Zakariaie, founder and CEO of Sensei, to talk about the science of the eye, a $2M technology problem solved with a commercial camera, and why fixing mental health starts with fixing measurement. Key Takeaways Mental health's biggest crisis isn't just a shortage of care — it's a measurement problem. Major depression, the most commonly diagnosed mental health condition in the U.S., is misdiagnosed approximately 65% of the time. PTSD, bipolar, and schizophrenia are misdiagnosed between 84–92% of the time.Sensei's diagnostic app shows patients a series of ocular stimuli for roughly 10.5 minutes, captures their eyes' responses via a standard smartphone camera, and outputs a binary diagnosis plus a severity score.The platform measures approximately 45 individual metrics across three categories: traditional ocular metrics (pupil size, blinks, saccades, gaze), iris dilator and sphincter dynamics (mapping sympathetic vs. parasympathetic nervous system activity), and heart rate and heart rate variability from facial video.Sensei is currently in Phase 3 clinical trials for a PTSD diagnostic, with an FDA submission planned for late 2025 and approval expected in 2027.About 16,000 people participated in pre-trial studies; the full dataset at submission is expected to reach approximately 30,000.The go-to-market strategy focuses on telehealth platform integration — partnering with companies like Spring Health, Talkspace, and BetterHelp to embed the diagnostic tool directly into existing care delivery workflows.Future expansion targets schizophrenia, bipolar disorder, and ADHD, with longer-term interest in neurodegenerative conditions like Alzheimer's and dementia.About David Zacharia David Zakariaie is the founder and CEO of Sensei, a mental health diagnostics company building the first FDA-regulatory-grade platform for diagnosing and monitoring PTSD, anxiety, and depression using AI-powered ocular biometrics. His path began at 15, when he attended Google I/O, received an early pair of Google Glass, and became fascinated with the scientific potential of the human eye. He left high school after 10th grade, taught himself to code, and launched the company in 2015. Resources & Links Mentioned Sensei: sensei.health (verify current URL)Mental Health Study (Phase 3 Trial Sign-Up): mentalhealthstudy.orgKaren Toffler Charitable Trust: tofflertrust.org (verify current URL)Parea Therapeutics (digital therapeutics reference)The CAPS-5 (Clinician-Administered PTSD Scale)The PCL-5 (PTSD Checklist for DSM-5)If You Enjoyed This Episode Subscribe to Research Renaissance wherever you listen to podcasts. If this conversation sparked something for you, share it with someone in healthcare, mental health advocacy, or neuroscience — this is the kind of work that needs more eyeballs on it. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    51 min

  4. Jun 3

    The Third Pillar: Why Sleep Apnea, Circadian Rhythms, and Cognitive Health Are More Connected Than You Think

    Are you trading your long-term brain health for late-night screen time? Dr. Paul Chung, physician and researcher at Northwestern University, joins host Deborah Westphal to reveal why sleep is far more than rest - and why ignoring it could cost you decades of cognitive health. Dr. Chung is an Assistant Professor at Northwestern University, a pulmonary and sleep medicine physician, and a 2023 Toffler Scholar. His research sits at the intersection of sleep, circadian biology, and Alzheimer's disease - with a special focus on adults with Down syndrome as a model for understanding cognitive decline. What You'll Learn in This Episode Why sleep is an active process of repair - not passive rest - and how it regulates your heart, brain, immune system, and metabolismWhat sleep apnea actually is (beyond snoring) and why it causes a body-wide stress response every single nightWhy sleep apnea remains dramatically underdiagnosed - even 60 years after being formally defined - and what patients say when asked why they skip sleep studiesThe shocking truth: a third of adults and children still aren't getting enough sleep, and the number is even worse for teenagersHow disrupted circadian rhythms are linked to the buildup of amyloid beta - the protein central to Alzheimer's diseaseWhy individuals with Down syndrome are an invaluable research population for understanding Alzheimer's progression in the broader populationWhat "slow wave activity" in sleep EEG data reveals about cognitive declineThe science of chronotherapy - why when you take a medication or vaccine may be just as important as what you takeNight owls vs. early birds: the genetic reality behind your body clock, and why society quietly punishes night owlsThe future of personalized sleep medicine - beyond CPAPKey Takeaway Sleep is the third pillar of health alongside diet and exercise - yet it's the one most people sacrifice first About Dr. Paul Chung Dr. Paul Chung is a physician and Assistant Professor at Northwestern University's Feinberg School of Medicine, specializing in pulmonary and sleep medicine. He is a 2023 Toffler Scholar whose research focuses on sleep EEG microstructure, actigraphy, and circadian rhythms as they relate to cognitive vulnerability and Alzheimer's disease - with a particular emphasis on adults with Down syndrome. Research inquiries: paul.chung@northwestern.edu (For clinical appointments, contact Northwestern Medicine directly.) Resources Mentioned Karen Toffler Charitable Trust - Funding innovative, early-stage health research: tofflertrust.org NIH INCLUDE Project - Initiative to increase Down syndrome research funding: www.nih.gov Alzheimer's Biomarkers Consortium for Down Syndrome (ABC-DS) - Large collaborative cohort study Northwestern University Feinberg School of Medicine - Sleep Medicine Program If this conversation opened your eyes to the power of sleep science, please subscribe, leave a review, and share it with someone who keeps saying they'll "sleep when they're dead." Your support helps us bring more groundbreaking researchers to this mic. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    53 min

  5. May 27

    Why One Gene at a Time Isn't Enough: A Pioneer's View on Autism, Transcriptomics, and Future Cures

    What if the key to understanding autism isn't one gene — but thousands working together? In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Daniel Gershwind, Gordon and Virginia McDonald Distinguished Professor of Human Genetics, Neurology, and Psychiatry at UCLA, and Associate Vice Chancellor for Precision Health. A true pioneer in neurogenomics, Dr. Gershwind has spent over two decades reshaping how we understand autism and complex brain disorders — from building one of the first autism gene banks to applying transcriptomic network methods that revealed the molecular landscape of the brain in entirely new ways. This conversation is as much about the science as it is about how science gets done — through collaboration, curiosity, and a willingness to tackle the problems others walk away from. Key Takeaways Genetics doesn't mean "everything is genetic" — all human disease has both genetic and environmental components, but genetics offers a powerful, tractable starting point for understanding causeLooking at gene networks (rather than single genes) transformed the field by making sense of hundreds or thousands of genes at once — and revealing how biological systems adapt and respond to disruptionAutism affects approximately 1 in 100 children today — not because rates have risen, but because our ability to diagnose it has dramatically improved over the past 30 yearsAbout 15% of people with autism can now be identified with a specific causative genetic mutation through whole genome or exome sequencing — pointing toward targeted, precision therapiesTranscriptomics (measuring RNA expression across the brain) revealed shared molecular patterns in autism brains across different patients — a surprising convergence that has since been validated in large sample sizesAutism, schizophrenia, and bipolar disorder share some molecular pathology but are mostly molecularly distinct — a finding only visible at the transcriptomic levelCRISPR activation (without genome editing) has already been used in lab models to restore normal neuronal firing in certain autism-linked epilepsy syndromes — a proof of concept for future therapiesAI is now being used to connect gene networks to existing drugs, potentially accelerating drug discovery without needing full mechanistic understandingNeurodegeneration (including Alzheimer's and frontotemporal dementia) is closer to clinical trials than autism — but the two fields are informing each other in real timeAbout the Guest Dr. Daniel Gershwind is the Gordon and Virginia McDonald Distinguished Professor of Human Genetics, Neurology, and Psychiatry at UCLA. He leads the Gershwind Lab and serves as Associate Vice Chancellor for Precision Health. He co-founded the Autism Genetic Resource Exchange (AGRE), which became the leading data resource for autism genetics research for over a decade, and has been instrumental in developing transcriptomic network approaches now used widely across the field. Resources & Links Karen Toffler Charitable Trust: karentoffler.orgAutism Genetic Resource Exchange (AGRE)UCLA Gershwind LabPsychENCODE ConsortiumEnjoyed this episode? Subscribe to Research Renaissance wherever you listen to podcasts, leave us a review on Apple Podcasts, and share this episode with anyone who cares about the future of brain health research. Every share helps bring this science to more people. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    58 min

  6. May 20

    The Brain's Plumbing Problem: A Neurologist-Scientist's Quest to Clear Alzheimer's Proteins

    What if one of the most promising frontiers in Alzheimer's research isn't just about what's building up in the brain - but how the brain clears it out? In this episode of Research Renaissance, host Deborah Westphal sits down with Dr. Tirth Patel, a neurologist and physician-scientist at UCLA and 2025 Toffler Scholar, to explore the cutting-edge science of brain clearance, tau protein, and the newly discovered lymphatic vessels surrounding the brain. This is a conversation about curiosity, persistence, and the kind of early-career science that could reshape how we understand and treat dementia. What You'll Learn in This Episode What tau protein is, why it "gunks up" the brain, and how it differs from amyloid beta in Alzheimer's diseaseThe recently discovered lymphatic vessels in the brain's meninges - and why they matter for clearing toxic proteinsHow sleep deprivation spikes tau and amyloid levels in the blood, and what that means for long-term brain healthThe glymphatic system: the brain's internal waste-clearance highway and its deep connection to sleepWhy aging slows down the brain's lymphatic drainage - and what researchers are doing about itThe genetics of Alzheimer's: the difference between causative mutations (APP, PS1, PS2) and risk factors like APOE4New FDA-approved blood tests and the promise of tau PET scans for better diagnosis and stagingThe latest treatments for Alzheimer's - how they work, their limitations, and what's coming nextWhy failure is one of the most undervalued tools in science - and what's missing in how the field handles negative dataA candid take on AI in biological research: where it helps, where it falls short, and whether it lets scientists failAbout Our Guest Dr. Tirth Patel is a neurologist and physician-scientist at UCLA, currently working in the lab of Dr. Jason Hinman. His research focuses on how the brain's meningeal lymphatic vessels clear tau protein from the brain to the bloodstream - a question with major implications for Alzheimer's disease and related dementias. Dr. Patel is a 2025 Toffler Scholar, supported by the Karen Toffler Charitable Trust. He is also the co-host of the podcast Recreational Science, where he and his colleague Dr. Lou Yang explore wacky but well-designed scientific studies to illuminate the scientific method. 📧 Reach Dr. Patel: tkpatel@mednet.ucla.edu Resources & Links Mentioned Karen Toffler Charitable TrustRecreational Science Podcast - co-hosted by Dr. Tirth Patel and Dr. Lou YangUCLA Department of NeurologyAlzheimer's Association resources on APOE4, tau, and amyloidLike what you heard? Subscribe to Research Renaissance on Apple Podcasts, Spotify, or wherever you listen. Leave us a review - it helps more people discover the science that matters. And share this episode with someone who cares about brain health, aging, or the future of medicine. Research Renaissance is presented by the Karen Toffler Charitable Trust. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    59 min

  7. May 13

    The Hidden Genome: How Mitochondrial DNA Shapes Aging and Disease

    The Hidden Genome Inside Every Cell Most of us learned that mitochondria are the “powerhouse of the cell.” What we didn’t learn? They carry their own DNA — and that DNA may hold crucial answers to aging, neurodegeneration, and rare childhood diseases. In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. Stefan Isaac, Assistant Professor at Boston University and 2025 Toffler Scholar, about how mitochondrial DNA is organized, regulated, and why its dysfunction may contribute to diseases ranging from Leigh syndrome to Alzheimer’s. 🎯 Key Takeaways Every cell contains hundreds to thousands of copies of mitochondrial DNAMitochondrial mutations accumulate over time and may drive aging and diseaseThere is a biochemical threshold — disease often appears when 60–80% of mitochondrial genomes are mutatedNew long-read sequencing technologies allow researchers to study mitochondrial DNA at single-molecule resolutionEmerging therapies aim to tip the balance toward healthy mitochondrial genomesMitochondrial dysfunction plays a role in:Rare primary mitochondrial diseasesNeurodegenerative diseases (Alzheimer’s, Parkinson’s)Neuromuscular and metabolic disorders 🧪 Featured Topics Mitochondrial gene expressionDNA accessibility and genome packagingInduced pluripotent stem cells (iPSCs)Cortical neuron modelsMutation drift vs. selective replicationEnvironmental exposure and mitochondrial healthAntibiotic-associated mitochondrial toxicity 🔬 About Our Guest Dr. Stefan Isaac Assistant Professor, Boston University Research focus: Mitochondrial genome regulation, replication, and dysfunction in aging and disease. If you found this conversation insightful: Follow Research RenaissanceShare this episode with a colleagueLeave a review on Apple Podcasts or SpotifySend it to someone interested in neuroscience, aging, or rare diseases The future of medicine begins with understanding the cell. To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    45 min

  8. May 6

    Rewiring Mental Health: Nature-Inspired Brain Medicine with Dr. Jacob Hooker

    What if the next breakthrough in mental health didn’t start in a lab — but in nature? In this episode of Research Renaissance, host Deborah Westphal speaks with Dr. Jacob Hooker, neuroscientist, entrepreneur, and CEO of Sensorium Therapeutics. Dr. Hooker shares how his journey from textile chemistry to molecular imaging led him to build a biotech company focused on nature-inspired treatments for anxiety and other neurological conditions. With nearly 20% of the U.S. population diagnosed with an anxiety disorder, the need for better treatments is urgent. Dr. Hooker explains why current psychiatric care often relies on trial-and-error prescribing — and how brain imaging, biomarkers, and computational tools may help match patients to the right treatment faster. This conversation explores the intersection of neuroscience, genetics, psychedelics, stigma, and precision medicine — and why solving even one patient’s journey can create ripple effects for millions. 🔑 Key Takeaways Why 85% of brain medicines originate from observations in natureThe science behind anxiety — and why it’s more than “just feelings”How EEG and imaging biomarkers could reduce trial-and-error prescribingThe resurgence of psychedelic research — and what it’s teaching usWhy unpredictability in modern life may be driving anxiety ratesThe founder journey from academia to biotech entrepreneurship⏱️ Episode Timestamps 00:00 – Welcome to Research Renaissance 01:00 – From textile chemistry to neuroscience 03:00 – Why anxiety became Sensorium’s first focus 05:00 – Nature as the origin of psychiatric medicines 10:00 – Psychedelics, drug development, and new mechanisms 13:00 – Social anxiety disorder and stigma 21:00 – Brain imaging and biomarker-guided treatment 27:00 – Why stopping medication can restart the cycle 29:00 – Is modern life increasing anxiety? 33:00 – Personal journey: growing up with mental illness 42:00 – Defining impact in mental health 👤 Guest Dr. Jacob Hooker  Neuroscientist, entrepreneur, and CEO of Sensorium Therapeutics  Founder of Ether in Mind (Substack) 🔬 About Sensorium Therapeutics Sensorium Therapeutics develops nature-inspired treatments for anxiety and related neurological conditions. Their approach integrates computational chemistry, molecular imaging, and biomarker strategies to personalize psychiatric treatment. 💬 Join the Conversation If this episode expanded your understanding of mental health science: Follow Research RenaissanceShare this episode with a colleague or friendLeave a review on Apple Podcasts or SpotifyVisit the Karen Toffler Charitable Trust to explore more conversationsTo learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

    46 min
See All (77)

About

Welcome to Research Renaissance, presented by the Karen Toffler Charitable Trust. We invite you into the stories, struggles, and breakthroughs shaping the future of human health. From cutting-edge brain science to discoveries transforming how we heal, adapt, and thrive, we explore the ideas that matter and the people behind them. Each episode features early-career researchers driven by curiosity, entrepreneurs turning bold ideas into lifesaving innovations, and leaders in investment, policy, and research who help move discoveries into the real world. Together, we look across diseases, technologies, and research fields to understand not just what is changing, but why it matters—for patients, families, and the future we all share. Join us as we uncover new insights, spark collaboration, and illuminate the science that can improve lives.

Information